Mindful Eating and Current Glycemic Control in Patients With Type 2 Diabetes

January 26, 2024 updated by: Ayse N Erbakan, Goztepe Prof Dr Suleyman Yalcın City Hospital

The Association of Mindful Eating With Current Glycemic Control in Patients With Type 2 Diabetes

The goal of this observational study is to learn about the association of the level of mindful eating with the current glycemic control in patients with type 2 diabetes. The researchers will compare different glycemic control levels with the participants mindfulness while eating. And secondly, the researchers will compare the levels of eating awareness of those with and without obesity.

Study Overview

Status

Completed

Conditions

Detailed Description

In type 2 diabetes, life style adaptations, mainly healthy eating, weight loss or control and exercise constitutes the foundation of type 2 diabetes management. In addition to regulating blood sugar levels, lifestyle modifications play a significant role in controlling risk factors such as hypertension and hyperlipidemia, delaying/preventing complications from developing, and even promoting diabetes regression. It is essential not only to focus on healthy food choices in dietary therapy but also to ensure patients achieve weight loss. Another crucial point is maintaining the continuity of these lifestyle changes.

It is reported that it is quite challenging for patients to make lifestyle changes, adapt to the offered treatments, and furthermore, sustain this as a way of life. Adherence to these dietary changes is crucial for long-term success in managing diabetes and achieving weight loss goals.

In a cross-sectional study conducted by Fanning and colleagues with 148 type 2 diabetic patients, it was found that "conscious eating" is associated with better diet adherence. In a review by Dunn et al., the available data strongly support the necessity of "conscious eating" as part of weight management programs. An American Heart Association statement highlights strong evidence that irregular eating patterns can make it difficult to maintain a healthy cardiometabolic profile, and emphasizes that conscious attention to mealtime and frequency can contribute to a healthier lifestyle and better management of cardiometabolic risk factors.

In this study, the aim was to investigate the degree of eating mindfulness of patients with type 2 diabetes, and compare it between patients who had good glycemic control and patients with poorly controlled glycemic.

Study Type

Observational

Enrollment (Actual)

448

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey
        • Istanbul Medeniyet University Goztepe Research and TRaining Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Individuals attending to the diabetes outpatient clinic with type 2 diabetes diagnosis for at least 6 months, and received treatment for diabetes

Description

Inclusion Criteria:

  • given consent to the study
  • having applied to Diabetes Outpatient Clinic for diabetes management
  • having diagnosed with type 2 diabetes for at least 6 months
  • having the mental competence to answer the questions in the questionnaire

Exclusion Criteria:

  • Inconclusive diagnosis of type 2 diabetes
  • having not received or not using any treatment for diabetes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mindful eating, its subgroups and diabetes control in patients with type 2 diabetes
Time Frame: baseline
To investigate the relationship between mindful eating and its subgroups with glycemic control, as evaluated by HbA1c, in individuals diagnosed with type 2 diabetes for at least 6 months.
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mindful eating, its subgroups and the presence of obesity in patients with type 2 diabetes
Time Frame: baseline
To investigate the relationship between mindful eating and its subgroups with obesity, as evaluated by body mass index, in individuals diagnosed with type 2 diabetes for at least 6 months.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ayşe N Erbakan, MD, Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcın City Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2019

Primary Completion (Actual)

November 30, 2019

Study Completion (Actual)

December 30, 2019

Study Registration Dates

First Submitted

January 14, 2024

First Submitted That Met QC Criteria

January 26, 2024

First Posted (Estimated)

January 29, 2024

Study Record Updates

Last Update Posted (Estimated)

January 29, 2024

Last Update Submitted That Met QC Criteria

January 26, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe